Denosumab + Alternative osteoporosis medications
Phase 3Terminated 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Osteogenesis Imperfecta (OI)
Conditions
Osteogenesis Imperfecta (OI)
Trial Timeline
Jul 26, 2018 → Mar 28, 2022
NCT ID
NCT03638128About Denosumab + Alternative osteoporosis medications
Denosumab + Alternative osteoporosis medications is a phase 3 stage product being developed by Amgen for Osteogenesis Imperfecta (OI). The current trial status is terminated. This product is registered under clinical trial identifier NCT03638128. Target conditions include Osteogenesis Imperfecta (OI).
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03638128 | Phase 3 | Terminated |
Competing Products
16 competing products in Osteogenesis Imperfecta (OI)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Teriparatide (FORTEO) + Placebos | Eli Lilly | Approved | 85 |
| Zoledronic Acid | Novartis | Phase 2 | 52 |
| Zoledronic Acid | Novartis | Phase 2 | 52 |
| Zoledronic Acid | Novartis | Phase 3 | 77 |
| Romosozumab + Bisphosphonate | Amgen | Phase 3 | 76 |
| Romosozumab | Amgen | Phase 1 | 32 |
| Denosumab | Amgen | Phase 3 | 76 |
| Fresolimumab | Sanofi | Phase 1 | 32 |
| SAR439459 + Placebo | Sanofi | Phase 1 | 32 |
| BPS804 | Ultragenyx Pharmaceutical | Phase 2 | 47 |
| Setrusumab | Ultragenyx Pharmaceutical | Phase 2/3 | 60 |
| Setrusumab | Ultragenyx Pharmaceutical | Phase 2 | 47 |
| BPS804 | Ultragenyx Pharmaceutical | Phase 2 | 47 |
| setrusumab | Ultragenyx Pharmaceutical | Phase 3 | 72 |
| setrusumab + zoledronic acid (optional) | Ultragenyx Pharmaceutical | Phase 2 | 47 |
| Bisphosphonate + Setrusumab | Ultragenyx Pharmaceutical | Phase 3 | 72 |